TP53 and cancer: The G1/S checkpoint is functionally inactive in most of the cancers mainly because of mutation in TP53 gene, therefore abrogating the G2/M checkpoint via WEE1 inhibition followed by DNA damage offers a promising therapeutic opportunity to kill cancer cells.